Abstract:The aggregation of amyloid-beta protein (A beta) into fibrillary deposits is implicated in Alzheimer's disease (AD), and inhibiting A beta aggregation and clearing A beta fibrils are considered as promising strategies to treat AD. It has been reported that resveratrol (RSV) and epigallocatechin-3-gallate (EGCG), two of the most extensively studied natural polyphenols, are able to inhibit A beta fibrillization and remodel the preformed fibrillary aggregates into amorphous, non-toxic species. However, the mechanisms by which RSV inhibits A beta(42) aggregation and disrupts A beta(42) protofibril, as well as the inhibitory/disruptive mechanistic similarities and differences between RSV and EGCG, remain mostly elusive. Herein, we performed extensive all-atom molecular dynamics (MD) simulations on A beta(42) dimers (the early aggregation state of A beta(42)) and protofibrils (the intermediate of A beta(42) fibril formation and elongation) in the absence/presence of RSV or EGCG molecules. Our simulations show that both RSV and EGCG can bind with A beta(42) monomers and inhibit the dimerization of A beta(42). The binding of RSV with A beta(42) peptide is mostly via pi-pi stacking interactions, while the binding of EGCG with A beta(42) is mainly through hydrophobic, pi-pi stacking, and hydrogen-bonding interactions. Moreover, both RSV and EGCG disrupt the beta-sheet structure and K28-A42 salt bridges, leading to a disruption of A beta(42) protofibril structure. RSV mainly binds with residues whose side-chains point inwards from the surface of the protofibril, while EGCG mostly binds with residues whose side-chains point outwards from the surface of the protofibril. Furthermore, RSV interacts with A beta(42) protofibrils mostly via pi-pi stacking interactions, while EGCG interacts with A beta(42) protofibrils mainly via hydrogen-bonding and hydrophobic interactions. For comparison, we also explore the effects of RSV/EGCG molecules on the aggregation inhibition and protofibril disruption of the Iowa mutant (D23N) A beta. Our findings may pave the way for the design of more effective drug candidates as well as the utilization of cocktail therapy using RSV and EGCG for the treatment of AD.

The Binding of Resveratrol to Monomer and Fibril Amyloid Beta

Synthesis and Biological Evaluation of Deferiprone-Resveratrol Hybrids As Antioxidants, Aβ1–42 Aggregation Inhibitors and Metal-Chelating Agents for Alzheimer's Disease

Resveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation.

Suppressive effect in vitro of resveratrol on ADP induced human platelet aggregation and its active mechanism]

Experimental and Theoretical Insights into the Inhibition Mechanism of Prion Fibrillation by Resveratrol and Its Derivatives

Molecular mechanisms of resveratrol and EGCG in the inhibition of A<sub>42</sub> aggregation and disruption of A<sub>42</sub> protofibril: similarities and differences

Resveratrol Induces the Conversion from Amyloid to Amorphous Aggregation of Β-Lactoglobulin

Understanding the Molecular Mechanisms of Polyphenol Inhibition of Amyloid β Aggregation

The resveratrol trimer miyabenol C inhibits β-secretase activity and β-amyloid generation.

Design, Synthesis, And Evaluation Of Resveratrol Derivatives As A Beta(1-42) Aggregation Inhibitors, Antioxidants, And Neuroprotective Agents

In Silico Study of Recognition Between Aβ40 and Aβ40 Fibril Surfaces: an N-Terminal Helical Recognition Motif and Its Implications for Inhibitor Design

Resveratrol Inhibits Β-Amyloid-induced Neuronal Apoptosis Through Regulation of SIRT1-ROCK1 Signaling Pathway.

Synthesis and evaluation of isoprenylation-resveratrol dimer derivatives against Alzheimer's disease.

Design, synthesis, and evaluation of multitarget-directed resveratrol derivatives for the treatment of Alzheimer's disease.

Atomistic Characterization of Binding Modes and Affinity of Peptide Inhibitors to Amyloid-Β Protein

Relationship between therapeutic activity and preferential targeting of toxic soluble aggregates by amyloid-beta-directed antibodies

Resveratrol Attenuates Aβ-Induced Early Hippocampal Neuron Excitability Impairment via Recovery of Function of Potassium Channels

Research Progress on Alzheimer's Disease and Resveratrol

Surface plasmon resonance biosensors for simultaneous monitoring of amyloid-beta oligomers and fibrils and screening of select modulators.

Pharmacodynamics in Alzheimer's Disease Model Rats of a Bifunctional Peptide with the Potential to Accelerate the Degradation and Reduce the Toxicity of Amyloid Β-Cu Fibrils.

Mechanism Exploration of Amyloid-β-42 Disaggregation by Single-Chain Variable Fragments of Alzheimer's Disease Therapeutic Antibodies.